Equities Analysts Offer Predictions for LENZ Q3 Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Analysts at HC Wainwright lifted their Q3 2026 EPS estimates for LENZ Therapeutics in a research report issued on Wednesday, August 12th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($1.02) per share for the quarter, up from their prior estimate of ($1.15). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($4.63) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ Q4 2026 earnings at ($1.00) EPS, FY2026 earnings at ($4.35) EPS, FY2027 earnings at ($4.14) EPS, FY2028 earnings at ($2.27) EPS, FY2029 earnings at ($0.85) EPS and FY2030 earnings at $0.63 EPS.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.03. LENZ Therapeutics had a negative net margin of 586.74% and a negative return on equity of 52.16%. The business had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $2.38 million.

Several other research analysts have also recently commented on the stock. Citigroup restated a “buy” rating on shares of LENZ Therapeutics in a report on Wednesday. Weiss Ratings downgraded shares of LENZ Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. Piper Sandler dropped their target price on shares of LENZ Therapeutics from $12.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday. Finally, Zacks Research cut LENZ Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 15th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.80.

LENZ Therapeutics Stock Performance

Shares of LENZ Therapeutics stock opened at $4.60 on Friday. The firm has a market cap of $144.53 million, a PE ratio of -1.12 and a beta of 0.65. The business’s 50 day simple moving average is $5.69 and its 200 day simple moving average is $9.04. LENZ Therapeutics has a 52-week low of $4.53 and a 52-week high of $50.40.

Hedge Funds Weigh In On LENZ Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in LENZ. Tower Research Capital LLC TRC grew its position in shares of LENZ Therapeutics by 51.4% in the second quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after purchasing an additional 477 shares during the last quarter. Quarry LP acquired a new stake in LENZ Therapeutics during the 3rd quarter worth approximately $27,000. JPMorgan Chase & Co. boosted its stake in LENZ Therapeutics by 8.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,222 shares of the company’s stock valued at $523,000 after purchasing an additional 861 shares during the period. BNP Paribas Financial Markets boosted its stake in LENZ Therapeutics by 93.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,951 shares of the company’s stock valued at $57,000 after purchasing an additional 944 shares during the period. Finally, Osaic Holdings Inc. grew its holdings in LENZ Therapeutics by 2,146.2% in the 2nd quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after buying an additional 1,116 shares in the last quarter. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.